Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna

Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data

Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead of BIO-Europe in Vienna, November 3-5, 2025.

European biotechs under increasing investor and regulatory pressure are turning to Avance Clinical’s proven Australian pathway to achieve first-in-human (FIH) and early proof-of-concept studies with:

• Startup timelines in as little as 5-6 weeks from final protocol to study approval through Australia’s streamlined regulatory frameworks (CTN/CTA) and Avance Clinical’s deep early phase expertise
• Globally accepted trial data, recognized by EMA, FDA, and other regulators
• Up to 43.5% cash rebate through Australia’s R&D tax incentive program
• Seamless progression to global trials through Avance Clinical’s GlobalReady program and worldwide partner network of 2,000+ sites